News & More

DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Its lead program is focused on modulating the Wnt/β-catenin signaling pathway to regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type 1 diabetes. It is currently in preclinical development. Backers included Roche Venture Fund, Eli Lilly and Company, Omnes, Boehringer Ingelheim Venture Fund, JDRF T1D Fund, and Adbio partners.

The global healthy eating platform Lifesum has unveiled a sleep tracking feature, which will allow its users to understand how their dietary choices impact their sleep patterns - and vice versa. The feature is made possible in partnership with Finland's ŌURA, the company behind the smart ring that delivers personalized health data, insights, and daily guidance -- and will build on their integration of Health Connect by Android to give Lifesum users another important layer of health data to track.

The company's Biolytica NEXUS health data platform is dubbed a revolutionary AI-driven analytics platform that aggregates, visualizes and analyzes a whole raft of data -- including genomics, blood, microbiome and epigenetic biomarkers, wearable devices, lifestyle data and more. Biolytica will use the funds to broaden its research and development efforts, scale its services to reach a wider client base and further collaborate with professionals in personalized and preventive healthcare.

The study, published in JAMA Internal Medicine, found that ChatGPT might actually be quite successful in providing high-quality, empathetic answers to patient questions during an era in which doctors and nurses are too busy to do so. John Ayers, a public health researcher at the University of California San Diego led the study, comparing two sets of written responses to real-world patient questions. One set was written by physicians, the other by ChatGPT. The patient questions were sourced from Reddit's AskDocs subreddit.

The company has announced a €7m extension to its Series A led by the Singapore-based global VC MassMutual Ventures. The new capital will be used to increase the commercialization of HelloBetter's digital therapeutics (DTx) products in Germany, as well as for further expanding in Europe and the United States.

Ciliatech is specialized in ophthalmology and its new class of implant designed to address the need to treat glaucoma durably and with zero adverse effects. The CID (Cilio-scleral Inter-positioning Device) implant aims to reduce intraocular pressure (IOP) without penetrating the anterior chamber or creating subconjunctival filtration, thus overcoming serious complications and shortcomings of other glaucoma surgical techniques. As CID is inserted between only two areas of the eye (between the ciliary body and the sclera), it offers the advantage of unlocking the natural uveoscleral pathway without altering the anterior segment of the eye.

TympaHealt provides a solution that enables fully digitized assessments of ear and hearing health to be performed in both traditional and community-based clinical settings. The Tympa Platform allows a broad range of professionals to perform digital otoscopy, microsuction wax removal, and hearing assessments. The company intends to use the funds to grow its team and services in the UK, across Europe and enter into the US.

According to SkyQuest, the market's growth will be significant due to factors such as the aging population, chronic diseases, government initiatives, cost-effectiveness, and technological advancements. Furthermore, the report states that Europe's aging population is expected to exceed 150 million by 2050, leading to increased demand for home healthcare services as elderly individuals prefer to receive care at their own homes. The report also reveals that home healthcare services can reduce healthcare costs by up to 30% compared to hospitalization or institutional care.

Regulatory mandates encouraging the implementation of digital health strategies have increased EHR adoption, which has aided the growth of the patient portal market. The patient portal market has grown in popularity as a result of government agencies' push for database interoperability and the ease of use provided by EHR in increasing patient engagement. Furthermore, as the number of projects in developing countries grows, so will the demand for patient portals.

The new fund, called Gilde Healthcare Venture&Growth VI, focuses on fast-growing companies developing solutions for better care at a lower cost. Gilde Healthcare invests in companies in Europe and North America active in digital healthcare, medical technology (MedTech) and therapeutics. The fund is backed by a balanced mix of international investors, including corporates, banks, pension funds, insurers, fund-of-funds, sovereign wealth funds, endowments, family offices, entrepreneurs and the Gilde team.